Tempest Therapeutics opened lower at $0.38, compared with its previous close of $0.40. In the last trading session, the stock traded between $0.37 and $0.40. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Tempest Therapeutics is now worth
$ 0.51
Resulting in a loss of
$ 99.49 (99.49%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.02 (-3.78%)
Day High
$0.40
Day Low
$0.37
Day Open
$0.38
Prev Close
$0.40
Volume
1,10,254
1W Return
-16.78%
1M Return
-48.10%
3M Return
-67.35%
6M Return
-80.31%
1Y Return
-92.06%
Market Cap ($ Mn)
8
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-247.49%
ROCE
-146.31%
EPS (TTM)
$-0.33
1 Week
-16.78%
1 Month
-48.10%
3 Months
-67.35%
6 Months
-80.31%
9 Months
-83.61%
Tempest Therapeutics files prospectus for resale of 9.53 million shares
Tempest Therapeutics registered resale of up to 9,534,164 common shares. Selling stockholders hold pre-funded, Series C, Series D, and placement agent warrants. Company receives no proceeds from resale but may gain cash from warrant exercises. Warrants issued in private placement dated September 11, 2026.
1mo agoTempest Therapeutics stock rises 66% on Hebei Senlang cell therapy option
Tempest Therapeutics shares rose 66.53% to $1.26 after-hours on Tuesday. Company secured exclusive option for Hebei Senlang's CD7-targeted CAR-T platform. Deal includes BCMA/GPRC5D dual-targeting candidate in Phase 1 trials. Stock had fallen 92.39% over the past 12 months prior to surge.
1mo agoTempest Therapeutics appoints Nicholas Rossettos as CFO, Trojanowski to resign
Justin Trojanowski to resign as Principal Financial Officer effective September 1. Nicholas Rossettos appointed as CFO and Principal Financial Officer. Leadership transition disclosed via SEC filing.
2mo agoTempest Therapeutics files prospectus for sale of 8.9 million shares
Tempest Therapeutics filed an SEC prospectus for share sale. Up to 8,910,579 shares of common stock are offered. Filing marks a procedural step in capital raising process.
2mo agoTempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline
Tempest Therapeutics reported a Q2 2026 net loss of $5.2 million, down from $7.9 million YoY, driven by lower R&D expenses. Year-to-date losses widened to $32.9 million due to $22.1 million in acquired in-process R&D charges. The company advanced its CAR-T pipeline with a new partnership for TPST-4003 and positive interim data for TPST-2003, while cash reserves declined to $0.8 million.
3mo agoTempest Therapeutics secures $50M equity purchase agreement with Lincoln Park
Tempest Therapeutics entered into a $50.0 million equity purchase agreement with Lincoln Park Capital on August 13, 2026. The deal allows for sales up to $25.0 million initially, with an automatic increase to the full amount subject to conditions. A registration statement must be filed with the SEC within 10 days.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Tempest Therapeutics is now worth
$ 0.51
Resulting in a loss of
$ 99.49 (99.49%)
Note: Past profits do not guarantee future returns.
